Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10701698	
Filing Date		2003-05-11	
First Named Inventor	BLAN	K, Ricardo	
Art Unit		3761	
Examiner Name	MARCETICH, Adam M.		
Attorney Docket Number		8496-US	

				U.S.	PATENTS	Remove
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	6223924		2001-05-01	Ek et al.	
	2	6621700		2003-09-16	Roman et al.	
	3	5993422		1999-11-30	Schafer	
If you wis	h to add	additional U.S. Paten	t citatio	n information pl	lease click the Add button.	Add
			U.S.P	ATENT APPLI	CATION PUBLICATIONS	Remove
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	19980032428	wo	1998-07-30	Novartis Nutrition AG	
	2	19930016595	wo	1993-09-02	Abbott Laboratories	
	3	19880006025	wo	1988-08-25	IPCO Corporation	
If you wis	h to add	additional U.S. Publis	hed Ap	plication citation	n information please click the Add	d button. Add
				FOREIGN PAT	TENT DOCUMENTS	Remove

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number		10701698
Filing Date		2003-05-11
First Named Inventor	BLAN	K, Ricardo
Art Unit		3761
Examiner Name	MARCETICH, Adam M.	
Attorney Docket Number		8496-US

Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² i	Kind Code4	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	Т5	
	1								
If you wisl	n to a	dd additional Foreign	 Patent Docum	ent citation	information p	lease click the Add butto	on Add		
			NON-PA	TENT LITE	RATURE DO	CUMENTS	Remove		
Examiner Initials*								T5	
	1	MCCARTY, M.F. "Nitric oxide deficiency, leukocyte activation, and resultant ischemia are crucial to the pathogenis of diabetic retinopathy/neuropathy. Preventive potential of antioxidants, essential fatty acids, chromium, ginkgolides, and pentoxylline" May 1998, MEDICAL HYPOTHESIS, vol. 50, nr. 5, pps 435-559 (XP008031833).							
	2	NAZIF, Naglaa M: "Phyloconstituents of Zizyphus spina-christi L. fruits and their antimicrobial activity" January 2002, FOOD CHEMISTRY, vol. 76, no. 1, pps 77-81 (XP002285033).							
BROCA, C et al.: "4-Hydroxyisoleucine Experimental Evidence of Its Insulinotropic and Antidiabelic Propertic October 1999, AMERICAN JOURNAL OF PHYSIOLOGY, vol. 277, no. 4, pps E617-E623 (X000090894).									
If you wisl	n to a	dd additional non-pate	ent literature do	cument cit	ation informa	tion please click the Add	button Add		
				EXAMINE	R SIGNATUF	RE			
Examiner Signature /Adam Marcetich/ Date Considered 9/15/201							9/15/2011		
*EXAMINI	ER: In	itial if reference consi	dered, whethe	r or not cita	ation is in con	formance with MPEP 60	9. Draw line through a		

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04.
² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3).
³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.
⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible.
⁵ Applicant is to place a check mark here if Empirish Inauquage translation is attached.

citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCESS CONSIDERED EXCEPT WHERE LINED THROUGH